Manulife (Manufacturers Life Insurance)
ARQT icon

Manulife (Manufacturers Life Insurance)’s Arcutis Biotherapeutics ARQT Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.9M Buy
503,856
+377,877
+300% +$9.64M 0.01% 782
2025
Q4 		$3.59M Buy
125,979
+69,956
+125% +$1.79M ﹤0.01% 1314
2025
Q3 		$1.06M Sell
56,023
-1,925
-3% -$30.4K ﹤0.01% 1825
2025
Q2 		$812K Sell
57,948
-145
-0.2% -$2.03K ﹤0.01% 1921
2025
Q1 		$909K Buy
58,093
+7,137
+14% +$101K ﹤0.01% 1851
2024
Q4 		$710K Sell
50,956
-1,547
-3% -$16.9K ﹤0.01% 2066
2024
Q3 		$488K Buy
52,503
+12,180
+30% +$120K ﹤0.01% 2303
2024
Q2 		$375K Buy
40,323
+9,537
+31% +$86.2K ﹤0.01% 2325
2024
Q1 		$305K Sell
30,786
-2,721
-8% -$20.3K ﹤0.01% 2393
2023
Q4 		$108K Buy
33,507
+12,465
+59% +$33.9K ﹤0.01% 2795
2023
Q3 		$112K Hold
21,042
– – ﹤0.01% 2768
2023
Q2 		$201K Buy
21,042
+4,650
+28% +$51.6K ﹤0.01% 2611
2023
Q1 		$180K Sell
16,392
-676
-4% -$9.78K ﹤0.01% 2596
2022
Q4 		$253K Buy
17,068
+2,837
+20% +$49.6K ﹤0.01% 2414
2022
Q3 		$272K Buy
14,231
+79
+0.6% +$1.79K ﹤0.01% 2366
2022
Q2 		$302K Buy
14,152
+1,931
+16% +$39.6K ﹤0.01% 2392
2022
Q1 		$235K Sell
12,221
-3,207
-21% -$54.3K ﹤0.01% 2666
2021
Q4 		$318 Buy
15,428
+517
+3% +$10.3K ﹤0.01% 2568
2021
Q3 		$356K Sell
14,911
-1,208
-7% -$27.6K ﹤0.01% 2541
2021
Q2 		$440K Buy
16,119
+3,144
+24% +$88.6K ﹤0.01% 2526
2021
Q1 		$375K Buy
12,975
+888
+7% +$27.7K ﹤0.01% 2466
2020
Q4 		$340K Buy
12,087
+2,311
+24% +$56.6K ﹤0.01% 2436
2020
Q3 		$286K Buy
+9,776
New +$261K ﹤0.01% 2325

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s ARQT Position: Q1 2026 in Review

Manulife (Manufacturers Life Insurance) increased its Arcutis Biotherapeutics (ARQT) stake by 300% in Q1 2026, buying an estimated $9.64M and bringing the position to 503,856 shares worth $11.9M. The position accounts for 0.01% of the portfolio, ranked #782.

Manulife (Manufacturers Life Insurance) first reported a position in ARQT in Q3 2020 and has held it in 23 quarters since. 270 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

  • Manulife (Manufacturers Life Insurance) held 503,856 shares of Arcutis Biotherapeutics worth $11.9M as of Q1 2026.
  • Manulife (Manufacturers Life Insurance) bought 377,877 Arcutis Biotherapeutics shares in Q1 2026, an estimated $9.64M.
  • Arcutis Biotherapeutics made up 0.01% of Manulife (Manufacturers Life Insurance)'s portfolio in Q1 2026, its #782 holding.
  • Manulife (Manufacturers Life Insurance) first reported a position in Arcutis Biotherapeutics in Q3 2020 and has held it in 23 quarters since.
  • 270 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q1 2026, filed 15 May 2026.